To print this article, all you need is to be registered or login on Mondaq.com.
Digital health technologies have brought a number of significant
breakthroughs to clinical trial programs, including faster patient
recruitment, more efficient data collection, and better tracking of
biometric information. But the new technologies also introduce
several complicated legal issues. Jones Day partners Maureen
Bennett and Cristiana Spontoni talk about privacy concerns,
security measures, changes to the informed consent process, data
integrity, and the integration of third-party technologies to
regulatory protocols.
The content of this article is intended to provide a general
guide to the subject matter. Specialist advice should be sought
about your specific circumstances.
The ever-changing healthcare policy landscape will witness at the federal level regulatory changes driven by the need to transform healthcare delivery, quality and innovation.
A bill introduced by a bipartisan group of Select Committee Members in the Senate and the House could severely impact U.S. companies' ability and desire to contract with biotechnology...
"[The] sin was methodological inconsistency[.]" The Sixth Circuit recently affirmed an MDL court's exclusion of the plaintiffs' only general causation expert and subsequent grant of summary...
In January 2024, the U.S. Government Accountability Office (GAO) issued a report highlighting current obstacles to the U.S. Food and Drug Administration's (FDA) timely and effective regulation...
FREE News Alerts
Sign Up for our free News Alerts - All the latest articles on your chosen topics condensed into a free bi-weekly email.